Tolerance Restoration
Reset the immune system to stop attacking the body
The goal is to restore the immune system’s tolerance of the body — to reset immunity in autoimmune disease so it stops attacking healthy tissue — rather than blunting all immune defense with broad, lifelong suppression.
In autoimmune diseases — lupus, type 1 diabetes, multiple sclerosis, and dozens more — the immune system turns on the body it should protect. Today’s mainstay is broad immunosuppression, which dampens harmful and protective immunity alike and must usually be taken for life. Restoring tolerance — retraining immunity to recognize the body as self again — would treat the cause, not just suppress the symptom. It is a high-impact companion to immune restoration.
We are building the capability to reset and retrain immunity toward tolerance: deeply clearing the immune cells driving an attack so the system rebuilds itself in balance, and teaching immunity to accept the body’s own tissues without disabling defense.
Resetting immunity, not just suppressing it
Resetting the immune system Clinical trials
Engineered immune cells (CD19 CAR-T) that deeply clear the B cells driving autoimmunity have produced drug-free remission in early trials for lupus and related diseases — the immune system appears to rebuild in balance.
Restoring self-tolerance Frontier
Approaches that teach immunity to accept the body’s own tissues — tolerance — aim to end the attack without broad suppression.
Targeting the attack precisely Frontier
Removing only the immune cells causing harm, while sparing protective immunity, is an active goal.
Rebuilding balanced immunity Frontier
After a reset, the immune system can repopulate — early evidence suggests it can return without the autoimmune attack.
Cited as evidence the capability is real — not as partners or endorsers.
Universities & institutes
Academic immunology and rheumatology centers (including the German groups whose CD19 CAR-T case series was reported in the New England Journal of Medicine) and autoimmune-cell-therapy programs worldwide.
Government & programs
National Institute of Allergy and Infectious Diseases (NIAID, NIH) · NIH autoimmune- and cell-therapy programs · FDA designations supporting autoimmune cell-therapy trials.
Enabling science base
CD19 CAR-T cell therapy · B-cell biology · immune-tolerance research · regulatory-T-cell approaches · iPSC-derived immune cells.
The technologies: CD19 CAR-T and related cell therapies that reset immunity by clearing disease-driving B cells; tolerance-inducing approaches and regulatory-T-cell strategies; and next-generation cell engineering (including off-the-shelf and iPSC-derived cells) aiming to make immune reset safer and more accessible.
Drug-free remission in trials Clinical trials
A New England Journal of Medicine case series and basket trials reported that single-infusion CD19 CAR-T produced sustained drug-free remission in severe lupus, myositis, and systemic sclerosis — the immune system reset rather than merely suppressed.
Multiple autoimmune diseases Clinical trials
Immune-reset approaches are being tested across several autoimmune diseases, with early remissions reported.
Toward accessible therapies Frontier
Off-the-shelf and stem-cell-derived versions aim to remove the cost and complexity of patient-specific cells.
Durable tolerance Frontier
Teaching lasting self-tolerance — not just clearing cells — remains an active frontier.
The honest challenges: these resets are early-stage trials, not approved autoimmune therapies — long-term safety and durability are still being established. The therapy is complex and costly today, and access is limited. Deeply clearing immune cells carries real short-term risks and temporary loss of some protection. And true, lasting tolerance is still being worked out. The remissions are striking and real; broad availability and proven durability are not here yet, and we say so.
The future, fully built
A person whose immune system attacks their own body has it reset toward balance: the cells driving the attack cleared, immunity rebuilt to tolerate the body again, autoimmune disease pushed into drug-free remission rather than suppressed for life. Immunity becomes something we retrain, not just hold down.
The proof, for this capability
Cited as evidence the capability is real, not as partners or endorsers.
CD19 CAR-T in autoimmune disease
A NEJM case series and basket trials reported sustained drug-free remission in severe lupus, myositis, and systemic sclerosis after a single CD19 CAR-T infusion. Stage: Clinical (trials).
Across multiple autoimmune diseases
Immune-reset cell therapies are in trials across several autoimmune conditions. Stage: Clinical (trials).
Tolerance & accessible therapies
Durable tolerance induction and off-the-shelf/iPSC-derived cells are advancing in research. Stage: Frontier.
Honest framing
Real organizations and studies are cited as evidence the capability is real — not as partners or endorsers. These are early trials, not approved autoimmune therapies; durability, safety, and access are unresolved, and we do not claim otherwise.
Help build this future
Every signature grows the movement to make immune-tolerance restoration real — and free at the point of need.